Reactions 1893, p102 - 12 Feb 2022

COVID-19-Vaccine-Pfizer-BioNTech

Acute generalised pustular psoriasis: case report

A man in his 40s [exact age not stated] developed acute generalised pustular psoriasis following administration of COVID-19-Vaccine-Pfizer-BioNTech.

The man, whose medical history was significant for psoriasis, presented to hospital for acute and rapidly progressive skin eruptions. Five days prior to the development of the rash, he had received his first dose of COVID-19-Vaccine-Pfizer-BioNTech [COVID-19 messenger RNA; route and dosage not stated]. He stated that the rash began with erythematous, tender patches and plaques on the abdomen and arms, which progressed to the legs and buttocks. Two days after the onset of the rash, an immediate care clinic diagnosed yeast infection. He was prescribed fluconazole and nystatin. The following day, he had significantly more surface area involvement of the rash, with worsening malaise. He was prescribed doxycycline and prednisone. He received methylprednisolone. One week after the development of the rash, he presented to hospital with worsening symptoms. On examination, he was ill-appearing with chills, decreased oral intake for several days, malaise and diffuse erythematous patches studded with fine pustules involving the trunk, arms and legs. He was admitted. Leukocytosis and acute kidney injury secondary to dehydration were noted.

The man received unspecified IV fluids, ciclosporin and infliximab. Biopsy showed psoriasiform dermatitis with intraepidermal neutrophilic pustules. Based on biopsy findings, he was diagnosed with acute generalised pustular psoriasis secondary to COVID-19-Vaccine-Pfizer-BioNTech.

Three days after the treatment, he showed significant improvement. He was discharged with clearance of the pustular psoriasis.

Perna D, et al. Acute generalized pustular psoriasis exacerbated by the COVID-19 vaccine. JAAD Case Reports 17: 1-3, Nov 2021. Available from: URL: http://doi.org/10.1016/j.jdcr.2021.08.035

803634533

S